Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/04/2017 12/05/2017 12/06/2017 12/07/2017 12/08/2017 Date
128.01(c) 127(c) 124.57(c) 128.73(c) 130.89(c) Last
1 306 260 869 532 974 249 891 187 731 478 Volume
-6.77% -0.79% -1.91% +3.34% +1.68% Change
More quotes
Financials ($)
Sales 2017 79,2 M
EBIT 2017 -476 M
Net income 2017 -474 M
Finance 2017 621 M
Yield 2017 -
Sales 2018 139 M
EBIT 2018 -503 M
Net income 2018 -498 M
Finance 2018 336 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 155x
EV / Sales2018 90,0x
Capitalization 12 871 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined... 
Sector
Biotechnology & Medical Research
Calendar
12/14 | 03:00pmPresentation
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
12/07 ALNYLAM PHARMACEUTICALS : to Webcast Presentation at BMO Capital Markets Prescri..
11/30 ALNYLAM PHARMACEUTICALS : U.S. Food and Drug Administration FDA Grants Alnylam B..
11/30 Melinta acquires Medicines Co.'s infectious disease unit
11/22 ALNYLAM PHARMACEUTICALS : U.S. Food and Drug Administration Grants Alnylam Break..
11/21 ALNYLAM PHARMACEUTICALS : Prices Public Offering of Common Stock
11/21 ALNYLAM PHARMACEUTICALS : Announces Proposed Public Offering of $675,000,000 of ..
11/21 ALNYLAM PHARMACEUTICALS : European Medicines Agency EMA Grants Alnylam Accelerat..
11/21 ALNYLAM PHARMACEUTICALS : Initiates Rolling Submission of New Drug Application N..
11/21 ALNYLAM PHARMACEUTICALS : Announces Closing of Public Offering of Common Stock a..
11/20 ALNYLAM PHARMACEUTICALS : Initiates Rolling Submission of New Drug Application t..
More news
Sector news : Biotechnology & Medical Research - NEC
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27DJBIOGEN : Alkermes Join Forces for Multiple Sclerosis Drug
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
12/08 Akari's Coversin successful in mid-stage PNH study
12/01 MEDICAL STOCKS : Investing For 2018
11/30 Biotechs one of top groups in bullish day
11/30 BIOTECH : Biding Its Time
11/21 YOUR DAILY PHARMA SCOOP : Roche Rallies, Alnylam Granted BTD, Celsion Soars
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Technical analysis trends ALNYLAM PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 150 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne L. Greenstreet Chief Operating Officer & Executive Vice President
Manmeet Singh Soni Chief Financial Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.239.21%12 871
CELLTRION, INC.--.--%22 034
IQVIA HOLDINGS INC32.81%21 333
INCYTE CORPORATION-6.54%20 382
LONZA GROUP54.74%19 270
SEATTLE GENETICS, INC.6.22%8 529